Key result
Low-dose aspirin increases major bleeding risk, but not in patients with diabetes.
Why the study?
Low-dose aspirin (≤ 300 mg/day) increases the risk of major bleeding, and individuals with diabetes have a higher baseline bleeding risk independent of aspirin exposure.
Does low-dose aspirin increase the risk of major bleeding in people with diabetes compared to the general population?
Does low-dose aspirin increase the risk of major bleeding in people with diabetes compared to the general population?
While low-dose aspirin increases major bleeding risk in general, this association is not seen in diabetic patients who already possess a high baseline bleeding risk.
Caution with low-dose aspirin may not apply in diabetes; hypothesis-generating and should not yet change practice.
Implications for practice and research: Low-dose aspirin (≤ 300 mg/day) increases the risk of major bleeding. Individuals with diabetes have a higher risk of bleeding independent of aspirin exposure. Future work should include comparative effectiveness studies to help inform treatment strategies based on individual risks, benefits, patient preferences and values.
No takes yet. Share an insight, caveat, or question.
Butalia et al. (2012) studied this question. Low-dose aspirin (≤ 300 mg/day) increases the risk of major bleeding, except in individuals with diabetes who already have a high baseline bleeding risk independent of aspirin exposure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: